Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2022.10.001).1 The aim of this European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) is to provide specific guidance on irAE management. Recommendations provided are based on evidence from the scientific literature, clinical experience and analogy to the treatment of autoimmune diseases (ADs), where appropriate.